Based: San Diego, CA
Investors: Abingworth Management, Clarus Ventures, Domain Associates, Scale Venture Partners, Thomas, McNerney & Partners, Undisclosed Investor
Scoop: Zogenix is developing CNS disorders and pain treatments. In December 2007 the company submitted an NDA for sumatriptan DosePro, a needle-free, disposable, subcutaneous delivery system for migraine. Zogenix is also working on a Phase III controlled release opioid product it in-licensed from Elan.